Safety Reading Notes

Read safety context beside the research guide.

The CBG and appetite/metabolic outcomes review source set should still be read with safety context in mind. Mechanistic or preclinical evidence should not be converted into consumer instructions, and product identity can change how closely a source applies. PMID 32899626

PubMed For Dummies Article

CBG and appetite/metabolic outcomes review Evidence Review: the long-form source walk-through

Quick read
  • CBG and appetite/metabolic outcomes review currently has 16 source-backed evidence row(s), so this page should be read as a research guide rather than a single conclusion. PMID 32899626
  • The evidence classes most visible in the row language are insufficient (5), mechanistic or pharmacological (5), preclinical (4), and preliminary human (2). PMID 33230154
  • The study-design language most visible in the row language is Animal study (7), Narrative or expert review (5), and Human clinical study (2). PMID 42105814
  • The repeated topics are Appetite and metabolic outcomes (16), which tells the reader where to start opening PubMed and DOI links. PMID 37305529

Start with the research question

CBG and appetite/metabolic outcomes review is built from 16 source-backed evidence row(s) and 16 research source(s). The current evidence classes read as insufficient (5), mechanistic or pharmacological (5), preclinical (4), and preliminary human (2), and the study-design language most often reads as Animal study (7), Narrative or expert review (5), and Human clinical study (2). PMID 32899626

The row-level question is not simply whether CBG and appetite/metabolic outcomes review is "good" or "bad." The useful question is what each row studied, what evidence class it received, and whether the source is close to the reader's actual question. The most repeated row topics are Appetite and metabolic outcomes (16). PMID 33230154

Human evidence 2 rows

Rows involving human participants, patients, or clinical source language. These rows are closer to everyday reader questions, but still depend on population, dose, route, comparator, and endpoint. PMID 41056638

Preclinical evidence 4 rows

Animal, cellular, or model-based rows. These can explain why a topic is being studied, but they should not be read as human-health instructions. PMID 36654096

Mechanistic evidence 5 rows

Rows about receptors, enzymes, channels, metabolism, binding, signaling, or pharmacology. These explain plausibility without proving a consumer outcome. PMID 27503475

Limits and uncertainty 5 rows

Rows where safety, tolerability, risk, product limits, or insufficient evidence need to stay visible next to the rest of the article. PMID 36397993

The lane labels are not a quality score. They are a reading method: keep human evidence, preclinical evidence, mechanisms, and uncertainty in separate mental boxes before deciding what a source can actually support. PMID 28125508

Where this page has the most source density

The largest bucket surfaced for this page is Appetite and metabolic outcomes: insufficient. That does not automatically mean the topic is settled; it means this is where the current source trail is densest. The next visible bucket is Appetite and metabolic outcomes: mechanistic or pharmacological, which gives readers another way to see what the literature repeatedly circles. PMID 32899626

Source density should be read with evidence posture. A bucket can contain many rows and still be limited if the studies are indirect, mixed, preclinical, product-specific, or mostly review-level. The paragraphs below name the buckets directly and keep each explanation connected to a source record. PMID 33230154

Bucket chapters: what the literature is circling

Appetite and metabolic outcomes: insufficient

5 research sources 5 rows (620, 622, 625, 627, 633) Evidence class: insufficient

This bucket summarizes source-backed rows focused on Appetite and metabolic outcomes: insufficient. It currently draws from 5 research source(s), so the exact study type matters. PMID 32899626

Read this bucket as an uncertainty marker. The source trail exists, but the current evidence posture is not strong enough for a broad plain-English conclusion. PMID 32899626

  • Evidence row 620

    CBG studied for Appetite and metabolic outcomes; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: appetite-related, weight,... PMID 32899626

  • Evidence row 622

    CBG studied for Appetite and metabolic outcomes; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: appetite-related, weight,... PMID 42105814

Appetite and metabolic outcomes: mechanistic or pharmacological

5 research sources 5 rows (621, 623, 624, 631, 634) Evidence class: mechanistic or pharmacological

This bucket summarizes source-backed rows focused on Appetite and metabolic outcomes: mechanistic or pharmacological. It currently draws from 5 research source(s), so the exact study type matters. PMID 33230154

Read this bucket as mechanism or pharmacology context. Mechanisms can make the biology easier to understand, but they are not the same thing as a demonstrated effect in people. PMID 33230154

  • Evidence row 621

    CBG studied for Appetite and metabolic outcomes; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: appetite-related, weig... PMID 33230154

  • Evidence row 623

    CBG studied for Appetite and metabolic outcomes; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: appetite-related, weight, glucose, or me... PMID 37305529

Appetite and metabolic outcomes: preclinical

4 research sources 4 rows (626, 628, 630, 635) Evidence class: preclinical

This bucket summarizes source-backed rows focused on Appetite and metabolic outcomes: preclinical. It currently draws from 4 research source(s), so the exact study type matters. PMID 27503475

Read this bucket as closer to a real-world question, then check the study population, dose, product, comparator, and endpoint before generalizing beyond the source. PMID 27503475

  • Evidence row 626

    CBG studied for Appetite and metabolic outcomes; evidence class: preclinical (population or model: Animal model mentioned; study design: Human clinical study; outcome measure: appetite-related, weight, glucose, or metabolic out... PMID 27503475

  • Evidence row 628

    CBG studied for Appetite and metabolic outcomes; evidence class: preclinical (population or model: Animal model mentioned; study design: Animal study; outcome measure: appetite-related, weight, glucose, or metabolic outcomes). PMID 28125508

Appetite and metabolic outcomes: preliminary human

2 research sources 2 rows (629, 632) Evidence class: preliminary human

This bucket summarizes source-backed rows focused on Appetite and metabolic outcomes: preliminary human. It currently draws from 2 research source(s), so the exact study type matters. PMID 34569849

Read this bucket as closer to a real-world question, then check the study population, dose, product, comparator, and endpoint before generalizing beyond the source. PMID 34569849

  • Evidence row 629

    CBG studied for Appetite and metabolic outcomes; evidence class: preliminary human (population or model: Human participants or patients mentioned; study design: Human clinical study; outcome measure: appetite-related, weight, g... PMID 34569849

  • Evidence row 632

    CBG studied for Appetite and metabolic outcomes; evidence class: preliminary human (population or model: Human participants or patients mentioned; outcome measure: appetite-related, weight, glucose, or metabolic outcomes). PMID 32795544

Human evidence, mechanisms, and safety are different lanes

This page currently separates human evidence (2 row(s)), mechanistic evidence (5 row(s)), and safety/tolerability context (0 row(s)). That separation is the heart of the site. Mechanistic evidence can make a topic biologically interesting, but it should not silently become a human outcome. PMID 32899626

Human evidence still depends on population, dose, route, duration, product identity, and endpoint. Safety rows belong in the same reading path as benefit-oriented rows because formulation, co-exposures, prescription medications, impairment context, and higher-risk populations can change how close a source is to a reader's question. PMID 33230154

What this does and does not mean

  • It means the page has a traceable source trail. It does not mean every bucket has the same clinical strength. PMID 34569849
  • It means mechanisms, animal models, human studies, safety rows, and insufficient-evidence rows are being kept visible as separate evidence types. PMID 31035309
  • It does not turn a preclinical mechanism into a consumer recommendation, and it does not treat one product, dose, route, or population as interchangeable with another. PMID 31941059

How to use the source table

The source-backed evidence table below is the audit trail. Each row keeps a public sentence connected to a source record when a PubMed ID or DOI is available. If a sentence feels important, the reader should be able to click through, inspect the study type, and decide whether the source is close to the question they care about. PMID 32899626

This is why the public page is intentionally layered. The top gives the reader a fast orientation. The bucket table groups repeated rows into readable topics. The article body explains the buckets using the actual evidence-row language. The source notes below walk through every evidence row before the source table repeats the technical trace. PMID 33230154

Source-reading checklist for CBG and appetite/metabolic outcomes review

  1. Open the linked PubMed or DOI record. PMID 32795544
  2. Check whether the source studied humans, animals, cells, chemistry, pharmacology, product testing, or a review of prior literature. PMID 21924288
  3. Compare the source product, dose, route, population, and endpoint to the question being asked. PMID 22543671
  4. Look for safety, tolerability, drug-interaction, impairment, pregnancy, pediatric, psychiatric, cardiovascular, and product-quality context before treating the bucket as settled. PMID 39192735
  5. Return to the evidence table when the article summary sounds too broad; the row is the audit unit. PMID 32899626

Source Notes

CBG and appetite/metabolic outcomes review source-by-source reading notes

These notes pull every evidence row on this page into the readable article body before the source table repeats the audit trail. Each note keeps the row language beside the PubMed or DOI link when available.

  1. Evidence row 620

    CBG studied for Appetite and metabolic outcomes; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: appetite-related, weight, glucose, or metabolic outcomes). PMID 32899626

    Evidence class: insufficient; Study design: Narrative or expert review. Source: It Is Our Turn to Get Cannabis High: Put Cannabinoids in Food and Health Baskets.
  2. Evidence row 621

    CBG studied for Appetite and metabolic outcomes; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: appetite-related, weight, glucose, or metabolic outcomes). PMID 33230154

    Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: In vitro and in vivo pharmacological activity of minor cannabinoids isolated from Cannabis sativa.
  3. Evidence row 622

    CBG studied for Appetite and metabolic outcomes; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: appetite-related, weight, glucose, or metabolic outcomes). PMID 42105814

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Cannabinoids in autoimmune diseases: mechanistic insights and translational challenges.
  4. Evidence row 623

    CBG studied for Appetite and metabolic outcomes; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: appetite-related, weight, glucose, or metabolic outcomes). PMID 37305529

    Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Cannabigerol modulates α2-adrenoceptor and 5-HT1A receptor-mediated electrophysiological effects on dorsal raphe nucleus and locus coeruleus neurons and anxiety behavior in rat.
  5. Evidence row 624

    CBG studied for Appetite and metabolic outcomes; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: appetite-related, weight, glucose, or metabolic outcomes). PMID 41056638

    Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Sphingolipid metabolism and insulin resistance - Does cannabigerol protect against experimental colitis induced by high-fat high-sucrose diet?
  6. Evidence row 625

    CBG studied for Appetite and metabolic outcomes; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: appetite-related, weight, glucose, or metabolic outcomes). PMID 36654096

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Cannabigerol and cannabichromene in Cannabis sativa L.
  7. Evidence row 626

    CBG studied for Appetite and metabolic outcomes; evidence class: preclinical (population or model: Animal model mentioned; study design: Human clinical study; outcome measure: appetite-related, weight, glucose, or metabolic outcomes). PMID 27503475

    Evidence class: preclinical; Study design: Human clinical study. Source: Cannabigerol is a novel, well-tolerated appetite stimulant in pre-satiated rats.
  8. Evidence row 627

    CBG studied for Appetite and metabolic outcomes; evidence class: insufficient (study design: Narrative or expert review; outcome measure: appetite-related, weight, glucose, or metabolic outcomes). PMID 36397993

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Pharmacological Aspects and Biological Effects of Cannabigerol and Its Synthetic Derivatives.
  9. Evidence row 628

    CBG studied for Appetite and metabolic outcomes; evidence class: preclinical (population or model: Animal model mentioned; study design: Animal study; outcome measure: appetite-related, weight, glucose, or metabolic outcomes). PMID 28125508

    Evidence class: preclinical; Study design: Animal study. Source: A cannabigerol-rich Cannabis sativa extract, devoid of [INCREMENT]9-tetrahydrocannabinol, elicits hyperphagia in rats.
  10. Evidence row 629

    CBG studied for Appetite and metabolic outcomes; evidence class: preliminary human (population or model: Human participants or patients mentioned; study design: Human clinical study; outcome measure: appetite-related, weight, glucose, or metabolic outcomes). PMID 34569849

    Evidence class: preliminary human; Study design: Human clinical study. Source: Survey of Patients Employing Cannabigerol-Predominant Cannabis Preparations: Perceived Medical Effects, Adverse Events, and Withdrawal Symptoms.
  11. Evidence row 630

    CBG studied for Appetite and metabolic outcomes; evidence class: preclinical (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: appetite-related, weight, glucose, or metabolic outcomes). PMID 31035309

    Evidence class: preclinical; Study design: Animal study. Source: Chemotherapy-induced cachexia dysregulates hypothalamic and systemic lipoamines and is attenuated by cannabigerol.
  12. Evidence row 631

    CBG studied for Appetite and metabolic outcomes; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: appetite-related, weight, glucose, or metabolic outcomes). PMID 31941059

    Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Neuroprotective and Neuromodulatory Effects Induced by Cannabidiol and Cannabigerol in Rat Hypo-E22 cells and Isolated Hypothalamus.
  13. Evidence row 632

    CBG studied for Appetite and metabolic outcomes; evidence class: preliminary human (population or model: Human participants or patients mentioned; outcome measure: appetite-related, weight, glucose, or metabolic outcomes). PMID 32795544

    Evidence class: preliminary human. Source: Urinary cannabinoid mass spectrometry profiles differentiate dronabinol from cannabis use.
  14. Evidence row 633

    CBG studied for Appetite and metabolic outcomes; evidence class: insufficient (study design: Narrative or expert review; outcome measure: appetite-related, weight, glucose, or metabolic outcomes). PMID 21924288

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Phytocannabinoids as novel therapeutic agents in CNS disorders.
  15. Evidence row 634

    CBG studied for Appetite and metabolic outcomes; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: appetite-related, weight, glucose, or metabolic outcomes). PMID 22543671

    Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Cannabinol and cannabidiol exert opposing effects on rat feeding patterns.
  16. Evidence row 635

    CBG studied for Appetite and metabolic outcomes; evidence class: preclinical (outcome measure: appetite-related, weight, glucose, or metabolic outcomes). PMID 39192735

    Evidence class: preclinical. Source: Ensiling conditions and changes of cannabinoid concentration in industrial hemp.